Primary Irritation Patch Test (PIPT) Study Conducted at NovoBliss Research for Shared Panel

Launched by NOVOBLISS RESEARCH PVT LTD · Dec 7, 2022

Keywords

ClinConnect Summary

The objective of this study is to evaluate the dermatological safety of the test products by 24 Hours patch test under complete occlusion on healthy adult human subjects and adequate representation of varied skin types (Oily, Dry, Normal, and Combination).

This is a single-center, evaluator-blinded study in healthy adult human subjects. Single 24-hour application of sponsor(s) provided test products along with positive and negative controls will be kept in contact with the skin of subjects under occlusion for at least 24 hours (+ 2 hours). The study can be conducted in a single group. Safe...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age: 18-65 years (both inclusive) at the time of consent.
• • 2. Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
• • 3. Subject with normal Fitzpatrick skin type III to V (Human skin colour determination scale).
• • 4. Females of childbearing potential must have a negative urine pregnancy test performed on Day 01 prior to patch application.
• • 5. Subject who do not have any previous history of adverse skin conditions and are not under any medication likely to interfere with the results.
• • 6. Subject is in good general health as determined by the Investigator on the basis of medical history.
• • 7. Subjects is willing to maintain the test patches in designated positions for 24 Hours.
• • 8. Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.
• • 9. Subject must be able to understand and provide written informed consent to participate in the study.
• • 10. Subject is willing to refrain from vigorous physical exercise during the study period and follow all the instruction given.
• Exclusion Criteria:
• • 1. Subject having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading.
• • 2. Medication which may affect skin response and/or past medical history.
• • 3. Subject having history of diabetes
• • 4. Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.
• • 5. Subject suffering from any active clinically significant skin diseases which may contraindicate.
• • 6. Subject having history of any skin diseases including eczema, atopic dermatitis or active cancer.
• • 7. Participation in any patch test for irritation or sensitization within the last four weeks.
• • 8. Subject having history of asthma or COPD (Chronic obstructive pulmonary disease).
• 9. Use of any:
• • i. Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application.
• • ii. Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application.
• • iii. Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and/or eye drops are permitted)
• • 10. Topical drugs used at application site.
• • 11. Subject with Self-reported Immunological disorders such as HIV positive, AIDS and/or systemic lupus erythematous.
• • 12. Individual who has a medical condition or is taking or has taken a medication which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk.
• • 13. Subject with known allergy or sensitization to medical adhesives, bandages.
• • 14. Participation in other patch study simultaneously.

Trial Officials